Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

This pilot study was designed to determine whether the low molecular weight heparin, enoxaparin, could be used for elective percutaneous coronary intervention (PCI) to provide antithrombotic effects without the full systemic anticoagulation that occurs with the use of unfractionated heparin. Sixty p...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1999-12, Vol.84 (12), p.1391-1395
Main Authors: Rabah, Maher M, Premmereur, Jerome, Graham, Mariann, Fareed, Jawed, Hoppensteadt, Debra A, Grines, Lorelie L, Grines, Cindy L
Format: Article
Language:English
Subjects:
Aged
Angina pectoris
Angina Pectoris - diagnostic imaging
Angina Pectoris - therapy
Angioplasty, Balloon, Coronary
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Coronary Angiography - drug effects
Coronary Disease - diagnostic imaging
Coronary Disease - therapy
Drug therapy
Enoxaparin - administration & dosage
Enoxaparin - adverse effects
Female
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Heparin - administration & dosage
Heparin - adverse effects
Humans
Infusions, Intravenous
Male
Medical research
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pilot Projects
Stents
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This pilot study was designed to determine whether the low molecular weight heparin, enoxaparin, could be used for elective percutaneous coronary intervention (PCI) to provide antithrombotic effects without the full systemic anticoagulation that occurs with the use of unfractionated heparin. Sixty patients were randomized to receive intravenous enoxaparin (1 mg/kg bolus dose) or unfractionated heparin at the time of coronary intervention. Laboratory testing was performed at baseline, 5 minutes, and 4 hours after study drug to test if a single bolus dose of intravenous enoxaparin can consistently achieve therapeutic antithrombotic effect, thus eliminating the need for multiple doses of heparin and closely monitoring levels of anticoagulation during PCI. Thirty percent of patients who received unfractionated heparin required a second bolus of intravenous heparin to achieve the target-activated clotting time of 300 seconds before PCI. Enoxaparin showed antithrombotic properties comparable to that of unfractionated heparin as measured by anti-Xa levels, with less inhibition of thrombin (factor IIa) at the time points measured (p
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00582-2